NCT00702754View on ClinicalTrials.gov

An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia

PHASE4CompletedINTERVENTIONAL
Enrollment

502

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

May 31, 2008

Study Completion Date

September 30, 2008

Conditions
Cervical Dystonia
Interventions
BIOLOGICAL

Botulinum Toxin Type B

Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.

Sponsors
All Listed Sponsors
lead

Solstice Neurosciences

INDUSTRY